You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued ProductCocaine hydrochloride (Cat. No. 2833) has been withdrawn from sale for commercial reasons.
Biological Activity for Cocaine hydrochloride
Competitive inhibitor of monoamine neurotransmitter transporters. Inhibits dopamine (DAT), serotonin (SERT) and noradrenalin (NET) transporters with Ki values are 267, 392 and 872 nM respectively. Psychostimulant.
Technical Data for Cocaine hydrochloride
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Cocaine hydrochloride
References for Cocaine hydrochloride
References are publications that support the biological activity of the product.
Fleckenstein et al (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur.J.Pharmacol. 406 1 PMID: 11011026
Torres et al (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat.Rev.Neurosci. 4 13 PMID: 12511858
View Related Products by Target
View Related Products by Product Action
Keywords: Cocaine hydrochloride, Cocaine hydrochloride supplier, inhibitors, inhibits, monoamine, transporters, noradrenalin, noradrenaline, NET, adrenergic, neurotransmitter, DAT, dopamine, serotonin, SERT, 5-HT, reuptake, 5-Hydroxytryptamine, Dopamine, Transporters, Adrenergic, 2833, Tocris Bioscience
3 Citations for Cocaine hydrochloride
Citations are publications that use Tocris products. Selected citations for Cocaine hydrochloride include:
Rennekamp et al (2016) σ1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol 12 552 PMID: 27239788
Ferraro et al (2012) A novel mechanism of cocaine to enhance DA d2-like receptor mediated neurochemical and behavioral effects. An in vivo and in vitro study. Neuropsychopharmacology 37 1856 PMID: 22453136
Luu and Malenka (2008) Spike timing-dependent long-term potentiation in ventral tegmental area DA cells requires PKC. J Neurophysiol 100 533 PMID: 18450581
Reviews for Cocaine hydrochloride
Average Rating: 5 (Based on 1 Review.)
Have you used Cocaine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
We tested the effect of chronic restraint stress on cocaine seeking in rats using both extinction- and abstinence-based animal relapse models. Rats were trained to press a lever for I.V. cocaine infusions (0.50 mg/kg/infusion) paired with a discrete tone+light cue in daily 3-h sessions. A main finding was that a history of chronic restraint stress was associated with increased cocaine priming-induced drug seeking.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.